1	Level and duration of IgG and neutralizing antibodies to SARS-CoV-2 in children with
2	symptomatic or asymptomatic SARS-CoV-2 infection
3	
4	
5	Running Title: SARS-CoV-2 antibody duration in children
6	
7	
8	Alka Khaitan ¹ *, Dibyadyuti Datta ¹ *, Caitlin Bond ¹ , Michael Goings ¹ , Katrina Co ¹ , Eliud O.
9	Odhiambo ¹ , Lin Zhang ² , Stephanie Beasley ² , Josh Poorbaugh ² *, Chandy C. John ¹ * ^a
10	
11	
12	*These authors contributed equally to this work
13	^a Corresponding author
14	
15	
16	¹ IRyan White Center for Pediatric Infectious Diseases and Global Health, Indiana University,
17	Indianapolis, IN, USA
18	² Eli Lilly and Company, Indianapolis, IN, United States
19	
20	
21	Corresponding author:
22	Ryan White Center for Pediatric Infectious Diseases and Global Health

Indiana University School of Medicine 1 2 1044 W. Walnut St., R4 402D 3 Indianapolis, IN, USA. 4 Email: chjohn@iu.edu 5 6 7 Keywords: COVID-19, SARS-CoV-2, children, neutralizing antibody, longevity 8 9 **Key Points:** Children have robust neutralizing and IgG antibody responses to SARS-CoV-2 10 infection after symptomatic or asymptomatic disease that are at least as strong as in adults. 11 Neutralizing antibodies in children last longer than in adults but wane over time. 12 13 14 15 16

1 Abstract

2

3	Background: There are presently conflicting data about level and duration of antibodies to
4	SARS-CoV-2 in children after symptomatic or asymptomatic infection.
5	Methods: We enrolled adults and children in a prospective 6-month study in the following
6	categories: 1) symptomatic, SARS-CoV-2 PCR+ (SP+; children, n=8; adults, n=16), 2)
7	symptomatic, PCR- or untested (children, n=27), 3) asymptomatic exposed (children, n=13) and
8	4) asymptomatic, no known exposure (children, n=19). Neutralizing and IgG antibodies to SARS-
9	CoV-2 antigens and Spike protein variants were measured by multiplex serological assays.
10	Results: All SP+ children developed nAb, whereas 81% of SP+ adults developed nAb. Decline in
11	the presence of nAb over 6 months was not significant in symptomatic children (100% to 87.5%,
12	p=0.32) in contrast to adults (81.3 to 50.0%, p=0.03). Among all children with nAb (n=22), nAb
13	titers and change in titers over 6 months were similar in symptomatic and asymptomatic
14	children. Levels of IgG antibodies in children to the SARS-CoV-2 Spike, RBD-1 and -2,
15	nucleocapsid and N-terminal domain antigens and to Spike protein variants were similar to
16	those in adults. IgG levels to primary antigens decreased over time in both children and adults,
17	but levels to three of six Spike variants decreased only in children.
18	Conclusions: Children with asymptomatic or symptomatic SARS-CoV-2 infection develop robust
19	neutralizing antibodies that remain present longer than in adults but wane in titer over time,
20	and broad IgG antibodies that also wane in level over time.
21	

1 Introduction

2

3	Since the onset of the COVID-19 pandemic, 28 million children had COVID-19 infection with
4	nearly 13,000 pediatric deaths globally ¹ . The latest COVID-19 surges increasingly affected
5	children yet COVID-19 vaccines were only recently approved for children over the age of 5 years
6	and no vaccine is available for children under 5. Understanding the breadth and durability of
7	SARS-CoV-2 immunity in children after natural infection is critical to guide future protective
8	measures for children.
9	
10	Children typically have milder symptoms and less severe disease with SARS-CoV-2 infection
11	than adults. One mechanism thought to mediate protection is the development of neutralizing
12	antibodies (nAb) to SARS-CoV-2, which have been shown to be predictive of protection from
13	symptomatic COVID-19 infection ² , and are often used as a correlate of protective immunity to

SARS-CoV-2. While there are numerous studies of humoral immunity in adults, studies in
children are limited, with conflicting results³⁻¹⁷. Two recent and large studies in children

16 demonstrated that children develop neutralizing antibodies at similar levels and with similar

17 duration to those seen adults after infection^{8,12}. Yet in earlier studies, children with severe or

18 mild to severe COVID-19 had lower nAb levels and duration than adults^{4,11,17}. It is not clear

19 whether age, severity of COVID-19 infection, presence of specific SARS-CoV-2 variants or other

20 factors are responsible for the different study findings.

- To evaluate how level and duration of neutralizing and IgG antibodies to SARS-CoV-2 differ in
 children vs. adults, and whether symptomatic vs. asymptomatic infection affects this course in
 children, we conducted a study in adults and children starting early in the pandemic in the
 United States (June 2020) and evaluated these responses over a 6 month period of variable
 SARS-CoV-2 transmission.
- б
- 7

1 Materials and Methods

2

3 Study population, enrollment and follow-up.

4 From June 18 to December 29, 2020, children (<18 years old) and adults were enrolled in the 5 Development of Immunity to SARS-CoV-2 after Exposure and Recovery (DISCOVER) study in 6 Indianapolis, Indiana. Written informed consent was obtained from all participants and/or 7 parents and verbal assent from children aged 7 to 17 years. Individuals were enrolled in 4 8 subject categories according to symptoms of and exposure to COVID-19 infection: 1) 9 symptomatic PCR+ (SP+), 2) symptomatic PCR- or untested (SP-), 3) asymptomatic exposed (AE) 10 and 4) asymptomatic, no known exposure(ANE). **Symptomatic** children included those who reported persistent cough, fever, chills, sore throat, shortness of breath, headache, new loss of 11 12 taste or smell, muscle pain or diarrhea 21 days to 3 months prior to study enrollment. SP+ had a 13 documented positive SARS-CoV-2 naso- or oropharyngeal PCR test and SP- had a negative PCR 14 test or were not tested. Asymptomatic children reported no symptoms of COVID-19 in the 3 months prior to study enrollment. AE children were in close contact with an individual with 15 16 symptoms and a positive SARS-CoV-2 PCR. ANE children had no known close contact with an 17 individual with confirmed or suspected COVID-19 requiring quarantine. Exclusion criteria 18 included acute illness at study enrollment, immunocompromising conditions, or receipt of 19 convalescent plasma.

1	Blood samples were collected at study enrollment and 6 months after enrollment. Vaccination
2	was available for adults but not children during the later follow-up period, and date of
3	vaccination for those vaccinated was recorded at the 6-month visit.
4	
5	Serological Assays
6	LuminexIIxMAPIItechnology is a multiplex, flow cytometry-based platform that allows the
7	simultaneous quantitation of many protein analytes in a single reaction ¹⁸ . A custom Luminex-
8	based assay was developed to measure serology and antibody ACE2-RBD binding inhibition in a
9	single assay as previously described ^{19,20} .
10	
11	Surrogate neutralizing antibodies
12	Patient serum samples were titrated (1:20 – 1: 4.3E8) in phosphate buffered saline-high salt
13	solution (PBS-HS; 0.01 M PBS, 1% [bovine serum albumin] BSA, 0.02% Tween, 300 mM NaCl).
14	Diluted serum samples were combined with Luminex [®] MAGPlex [®] microspheres coupled
15	with individual antigens and a recombinant, labelled RBD-Phycoerythrin (PE) protein and
16	incubated for 60 minutes to allow endogenous antibodies to bind to either recombinant RBD-
17	PE or antigen-coated Luminex beads. The solution was placed on a magnet, collecting
18	the MAGPlex beads, while the supernatant was transferred to a new plate. The transferred
19	solution was combined with ACE2 coated beads and incubated for 60 minutes; remaining beads
20	were washed and incubated for 60 minutes with anti-IgG-PE beads to detect bound
21	antibodies. All beads on both plates were washed and resuspended in a PBS-1% BSA solution
22	and read using a Luminex@FlexMAP@3D System with xPONENT Software. The titer was

1	evaluated from the median fluorescence intensity (MFI) and the ability of the endogenous
2	antibodies to inhibit RBD-ACE2 binding was calculated based on the half maximal inhibitory
3	concentration, IC50, which represents the antibody titer where the ACE2-RBD binding is
4	reduced by half. The ACE2 binding inhibition potency was assessed using the inverse of IC50.
5	
6	Immunoglobulin G to SARS-CoV-2 antigens
7	Antigen-coated microspheres were used to detect and quantitate endogenous IgG antibodies
8	against SARS-CoV-2 proteins, including spike-NTD and several mutant RBD epitopes (Table S1).
9	Testing was done before widespread Delta and Omicron variant infections and antibodies to
10	these variants were not tested.
11	
12	Statistical Analysis
12 13	Statistical Analysis For the serial dilution-based serology assay, titer was calculated based on interpolating assay
13	For the serial dilution-based serology assay, titer was calculated based on interpolating assay
13 14	For the serial dilution-based serology assay, titer was calculated based on interpolating assay values that straddled the pre-determined "cut point" ¹⁹ . To calculate IC50 of data from the
13 14 15	For the serial dilution-based serology assay, titer was calculated based on interpolating assay values that straddled the pre-determined "cut point" ¹⁹ . To calculate IC50 of data from the ACE2 neutralization component of the serology assay, a 4-parameter logistic function was
13 14 15 16	For the serial dilution-based serology assay, titer was calculated based on interpolating assay values that straddled the pre-determined "cut point" ¹⁹ . To calculate IC50 of data from the ACE2 neutralization component of the serology assay, a 4-parameter logistic function was used to estimate the absolute IC50 based on 1/dilution factor. If a sample indicated no
13 14 15 16 17	For the serial dilution-based serology assay, titer was calculated based on interpolating assay values that straddled the pre-determined "cut point" ¹⁹ . To calculate IC50 of data from the ACE2 neutralization component of the serology assay, a 4-parameter logistic function was used to estimate the absolute IC50 based on 1/dilution factor. If a sample indicated no
13 14 15 16 17 18	For the serial dilution-based serology assay, titer was calculated based on interpolating assay values that straddled the pre-determined "cut point" ¹⁹ . To calculate IC50 of data from the ACE2 neutralization component of the serology assay, a 4-parameter logistic Ifunction was used to estimate the absolute IC50 based on 1/dilution factor. If a sample indicated no neutralization, the IC50 was imputed to 1 (20 times the maximum 1/dilution factor).
13 14 15 16 17 18 19	For the serial dilution-based serology assay, titer was calculated based on interpolating assay values that straddled the pre-determined "cut point" ¹⁹ . To calculate C50 of data from the ACE2 neutralization component of the serology assay, a 4-parameter logistic function was used to estimate the absolute IC50 based on 1/dilution factor. If a sample indicated no neutralization, the IC50 was imputed to 1 (20 times the maximum 1/dilution factor).

1	comparisons was done in the primary analysis because only two comparisons (by time point or
2	by group at each time point) were performed, and none was made for the secondary analysis
3	because it was exploratory. Evaluation of antibody decay/half-life was performed using
4	exponential growth/decay equation for each individual in GraphPad Prism 9. Statistical analyses
5	were conducted using Stata V16 (College Station, TX: StataCorp LP) and figures were created
6	using GraphPad Prism 9.

7

1 Results

3	Demographic characteristics of children and adults in the study and SARS-CoV-2 epidemiology
4	in Indiana at the time of the study. 94 children and 344 adults were enrolled in the study
5	(Figure 1). For this study on duration of antibodies, we included only children and adults who
6	had samples collected at enrollment and 6 months after enrollment, and with the focus on
7	children and limited testing capacity, we tested children from all 4 groups but only adults with
8	COVID-19 (SP+). From the individuals with samples at both time points, all children with COVID-
9	19 (SP+, n=8) and 23 of 58 SP+ adults were tested, as well as 27/29, 13/13 and 19/27 children
10	from the SP-, AE and ANE groups (Figure 1). Local state and county case rates of COVID-19
11	during the study period relative to sample collection times are shown in Figure S1. Pediatric
12	participants were 6 months to 17 years old (Table 1). ANE children were significantly older than
13	AE children. There were no differences in sex between categories. 13% of adults and 13% of
14	children were Black, and 13% of adults and 6% of children were Hispanic. There were no Asian
15	or Native American participants in the group tested.
16	
17	Children with symptomatic SARS-CoV-2 infection develop neutralizing antibodies more
18	frequently than asymptomatic exposed or non-exposed children, but titers among antibody-
19	positive children do not differ in symptomatic vs. asymptomatic children
20	One hundred percent of SP+ children developed neutralizing antibodies (nAb) to SARS-CoV-2
21	compared to 30%, 39% and 5% in the SP-, AE and ANE groups, respectively (Fig 2A). Antibody
22	titers among nAb positive symptomatic vs. asymptomatic children did not differ (Figure 2C).

1	
Т	

2	Neutralizing antibody seroprevalence and titers decrease in children with symptomatic or
3	asymptomatic SARS-CoV-2 infection after 6 months. Among the 22 children with nAb at
4	enrollment, 17 had nAb at 6 months (Figure 2B, p=0.03). Titers decreased significantly in
5	children with symptomatic or asymptomatic infections (Figure 2C).
6	
7	Children with symptomatic SARS-CoV-2 infection develop neutralizing antibodies to SARS-
8	CoV-2 at a similar proportion and level to adults, and for a longer duration.
9	We next compared nAb presence titers and duration between SP+ children and adults
10	(unvaccinated between visits, n=16). All children (100%) developed nAb whereas only 81% of
11	adults developed nAb (Fig 3; Table S1). At 6 months, 88% of SP+ children had nAb and only 50%
12	of SP+ adults had nAb present (Fig 3; Table S2). Thus a greater proportion of adults lost nAb by
13	6 months. Neutralizing antibody titers decreased in both SP+ children and adults over 6
14	months, and the mean difference in neutralizing antibody titers was greater in adults than
15	children, but this difference was not statistically significant (Fig 3; Table S2).
16	
17	Children with COVID-19 develop IgG antibodies to SARS-CoV-2 antigens and variants at
18	similar or higher levels to adults with COVID-19, and have similar decreases in antibody levels
19	6 months after initial infection. We next compared IgG antibodies to different SARS-CoV-2
20	proteins between adults and children with COVID-19 (the SP+ group), specifically examining
21	total spike protein (ST4), RBD 1 and 2, nucleocapsid protein (NCP) and N-terminal Domain (NTD;
22	Table S1). At initial visit, children had similar antibody levels as adults, and higher levels of RBD1

1	lgG compared with adults (Fig 4, Table S3). Children and adults had significant decreases in
2	antibody levels to RBD2 and NCP, while only children had significant decreases RBD1, and there
3	were no significant differences in antibody levels to ST4 or NTD in children or adults (Fig 4,
4	Table S3). SP-, AE and ANE had no changes in these IgG levels in the 2 nd visit (Fig S1).
5	
6	Given the continual emergence of novel SARS-CoV-2 variants, we also evaluated IgG antibodies
7	to a several Spike protein variants (Table S1). These variants did not include the Delta or
8	Omicron variants, which were not well established at the time of testing. SP+ children
9	developed robust IgG antibodies to every variant tested, and had higher levels of antibodies to
10	the E484Q and K417N variants than SP+ adults (Fig 4, Table S3). IgG antibodies to all Spike
11	variants decreased significantly in SP+ children over time, but IgG antibodies to 3 of the Spike
12	variants did not differ significantly over time in SP+ adults (Fig 4, Table S3). We also examined
13	changes in IgG antibiotics in SP-, AE and ANE. SP- had decreases in levels of IgG to E484Q and
14	d69-70 NTD, but asymptomatic children had no change in IgG levels at 6 months (Table S4),
15	likely reflecting the large proportion of children who were neutralizing antibody negative in
16	these groups at baseline (Fig S1). Neither neutralizing antibodies nor IgG antibodies in any child
17	group correlated with age (all p>0.05)
18	
19	
20	
21	Vaccinated adults develop neutralizing and IgG antibody titers to multiple SARS-CoV-2
22	antigens higher than those after infection, and have a slow linear decrease in neutralizing

1	antibody titers over time. Vaccines were unavailable to children during our study period, but 7
2	SP+ adults received COVID-19 vaccine between the enrollment and 6-month visits. We
3	compared antibody titers at the 6-month visit between vaccinated and unvaccinated adults. All
4	vaccinated adults had nAb at the 6 month visit whereas only 50% of unvaccinated adults had
5	nAb in the follow up visit (Fig 5A). In vaccinated adults, nAb titers rose to levels higher than
6	those with natural infection (Fig 5B). However, when we examined nAb titers relative to the
7	time of vaccination, nAb titers decreased as the days post-vaccination increased (Fig 5C).
8	Antibody responses to SARS-CoV-2 spike, RBD 1 and 2 and NTD increased after vaccination (Fig
9	S3, Table S5), but antibodies to NCP decreased in both vaccinated and unvaccinated adults, as
10	expected since the vaccine targets Spike protein. Antibody levels to Spike protein variants were
11	also increased after vaccination, whereas unvaccinated adults had decreases in these antibody
12	levels at the follow up visit (Fig S3, Table S5).
13	

1 Discussion

2

3 In this study, we show that children with symptomatic or asymptomatic SARS-CoV-2 infection 4 develop robust neutralizing antibodies and that these neutralizing antibodies persist in children 5 with symptomatic SARS-CoV-2 infection at a greater proportion than in adults at 6 months after 6 infection, but titers wane over time in both children and adults. Children with symptomatic 7 SARS-CoV-2 infection also develop IgG antibodies to multiple SARS-CoV-2 antigens and Spike 8 antigen variants at similar or higher levels to adults, and with a generally similar decrease over 9 6 months, though for some antigens the decrease was greater in children than adults. Finally, 10 we show that adults vaccinated against SARS-CoV-2 between the first and second visits develop levels of neutralizing and IgG antibodies significantly higher than with infection alone. The 11 12 findings demonstrate the importance of evaluating neutralizing antibodies in studies of the 13 immune response to SARS-CoV-2 in children and adults, as the IgG antibody levels to some antigens showed a greater decrease in children than adults, whereas a higher proportion of 14 children than adults retained neutralizing antibodies to SARS-CoV-2 at 6 months. 15

16

Our results support recent studies showing similar or higher level and greater duration of neutralizing antibodies in children than adults after SARS-CoV-2 infection^{8,9,12}, but differ from other studies that showed lower levels of neutralizing antibodies¹⁷ or IgG antibodies to the Spike protein⁴ and shorter duration of neutralizing or IgG antibodies in children compared to adults^{4,11}. Our results suggest that children develop robust neutralizing antibody responses as well as antibodies to multiple antigens variants after initial SARS-CoV-2 infection. Importantly

1	these responses remain present for at least 6 months, though titers decrease over time.
2	Pediatric responses are at least as robust as adults, and a higher proportion of children
3	maintain neutralizing antibodies at 6 months compared to adults. Children in this study were
4	not vaccinated, so we could not compare titers after vaccine to titers after infection. As in other
5	studies, adults developed much higher IgG and neutralizing antibody levels after infection
6	followed by vaccination ²¹ . Pediatric vaccine studies also show significantly higher nAb levels
7	after vaccination ²²⁻²⁴ , and demonstrate that vaccinated children have greater protection against
8	severe COVID-19 than unvaccinated children ²⁵ . Together, the study findings support a robust
9	immune response in children, but show waning of neutralizing antibodies over time, supporting
10	the need for vaccination and for studies on antibody kinetics in children after vaccination.
11	
12	Potential reasons for differences in the pediatric studies may include the age of children,
12 13	Potential reasons for differences in the pediatric studies may include the age of children, disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant
13	disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant
13 14	disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant in circulation at the time of the study. Regarding the effects of age, in a subanalysis we found
13 14 15	disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant in circulation at the time of the study. Regarding the effects of age, in a subanalysis we found no correlations between age and levels of nAb or tested IgG. Our study showed, as did one
13 14 15 16	disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant in circulation at the time of the study. Regarding the effects of age, in a subanalysis we found no correlations between age and levels of nAb or tested IgG. Our study showed, as did one prior study, a decrease in IgG antibodies to some SARS-CoV-2 antigens in children but not
13 14 15 16 17	disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant in circulation at the time of the study. Regarding the effects of age, in a subanalysis we found no correlations between age and levels of nAb or tested IgG. Our study showed, as did one prior study, a decrease in IgG antibodies to some SARS-CoV-2 antigens in children but not adults ⁴ , but the prior study did not evaluate neutralizing antibodies, which we show decreased
13 14 15 16 17 18	disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant in circulation at the time of the study. Regarding the effects of age, in a subanalysis we found no correlations between age and levels of nAb or tested IgG. Our study showed, as did one prior study, a decrease in IgG antibodies to some SARS-CoV-2 antigens in children but not adults ⁴ , but the prior study did not evaluate neutralizing antibodies, which we show decreased less frequently in children than adults. We used a surrogate neutralizing assay here which was
13 14 15 16 17 18 19	disease severity, various serological testing modalities and the predominant SARS-CoV-2 variant in circulation at the time of the study. Regarding the effects of age, in a subanalysis we found no correlations between age and levels of nAb or tested IgG. Our study showed, as did one prior study, a decrease in IgG antibodies to some SARS-CoV-2 antigens in children but not adults ⁴ , but the prior study did not evaluate neutralizing antibodies, which we show decreased less frequently in children than adults. We used a surrogate neutralizing assay here which was previously been reported to be strongly correlated with levels of neutralizing antibody

1	asymptomatic infection ¹⁷ . In the second study, children also had a reduced breadth of
2	antibodies, and predominantly generated antibodies to the S but not N antigen ¹⁷ . In contrast,
3	the present study confirms the findings of three other studies that show children, whether
4	symptomatic or asymptomatic, make neutralizing antibodies at similar or higher titers to adults,
5	also generate antibodies to multiple SARS-CoV-2 antigens, and retain neutralizing antibodies
6	longer than adults ^{8,9,12} . The present study adds to the prior studies in strongly supporting the
7	robust acquisition of IgG and neutralizing antibodies in children after symptomatic or
8	asymptomatic SARS-CoV-2 infection.
9	
10	Children in our cohort developed antibodies to multiple SARS-CoV-2 variants, but we did not
11	have the antigens for Delta or Omicron variants, so could not determine if IgG antibodies
12	developed against these variants. High neutralizing antibody levels were shown to correlate
13	with protection against these variants of concern (VOC), and children had relatively high
14	neutralizing antibody titers, but it is unclear if they would be high enough to protect against
15	VOC, particularly against Omicron. Recent data demonstrate that children develop nAb to
16	Omicron, but at significantly lower levels than wild type ^{22,24} . Similarly, mRNA COVID-19 vaccines
17	were shown to elicit neutralizing antibodies against Omicron in children and adolescents but at
18	lower levels than nAb to wild type ^{22,23} . Based on the epidemiology of Omicron infections in
19	children, which showed substantial transmission in areas in which many children had been
20	previously exposed to virus ^{26,27} , it is unlikely that the neutralizing antibodies generated by non-
21	Omicron variant infection would be sufficient to protect against Omicron.
22	

1

2	The relatively small sample size (22 children with SARS-CoV-2 infection and samples at
3	enrollment and follow-up), absence of children with severe SARS-CoV-2 infection, lack of
4	testing for IgG against Delta or Omicron variants, and lack of testing of cellular immunity, which
5	plays a critical role in memory responses to COVID-19 infection ^{8,28-31} , are all study limitations.
6	However, the study strengths, notably the evaluation of antibodies over time in children and
7	adults, evaluation of neutralizing antibodies and IgG antibodies against multiple Spike protein
8	variants, and the inclusion of testing in asymptomatic children, provide valuable new data on
9	level and duration of antibody response in children after SARS-CoV-2 infection.
10	
11	In conclusion, our study shows that the neutralizing antibody response to SARS-CoV-2 infection
12	in children after symptomatic or asymptomatic infection is at least as strong as in adults and
13	lasts longer in children than in adults but does wane over time in both children and adults. IgG
14	antibodies to some SARS-CoV-2 antigens showed a greater decrease in children than adults, but
15	the more functionally important neutralizing antibodies showed a greater decrease in adults
16	than children, highlighting the importance of evaluating neutralizing antibodies when assessing
17	changes in immunity over time. Now that SARS-CoV-2 vaccines are available for children,
18	studies of post-vaccination antibody responses in children will be important to determine the
19	extent to which these vaccines augment and prolong the duration and breadth of antibody
20	response, as they have in adults.
21	

1 Acknowledgements

- 2 We thank the participants in this study. This work was supported by the Riley Children's
- 3 Foundation and the Indiana University School of Medicine Department of Pediatrics.

- 5
- 6

1 Figure Legends

2

- 3 Figure 1. Study flowchart
- 4

5	Figure 2. Neutralizing antibody (nAb) prevalence and titers at baseline and 6-month follow-up
6	in (A) children according to study group, (B) all children with nAb at baseline, and (C)
7	comparing children who were in the symptomatic groups to asymptomatic
8	groups. Prevalence compared by visit using McNemar's test and by study cohort using Fisher's
9	exact test, with Bonferroni correction for pairwise comparisons. Red dots and lines represent
10	median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by
11	study cohort using Wilcoxon rank-sum test. #significantly different than all other groups;
12	*p<.05, **p<.001
13	
14	Figure 3. Prevalence and titers of neutralizing antibodies (nAb) at study baseline and 6-month
15	follow-up in SARS-CoV-2 PCR-positive, symptomatic unvaccinated children and adults.
16	Prevalence compared by visit using McNemar's test and by age group using chi-squared test.
17	Red dots and lines represent median of titers. Titers compared by visit using Wilcoxon
18	matched-pairs signed-rank test and by age group using Wilcoxon rank-sum test.
19	
20	Figure 4. Titers at study baseline and 6-month follow-up in SARS-CoV-2 PCR-positive,
21	symptomatic unvaccinated children (n=8) and adults (n=16). Red dots and lines represent

22 median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by

age group using Wilcoxon rank-sum test; *p<.05, **p<.01. Antigen definitions included in
 methods section

- 3
- 4 Figure 5. Prevalence (A) and titers (B) of neutralizing antibodies (nAb) at baseline and 6-
- 5 month follow-up in adults who are not vaccinated (NV, n=16) and vaccinated after first visit
- 6 (V, n=7), and (C) association between titers of nAb at 6-month follow-up and days since first
- 7 vaccination dose in adults who were vaccinated. Prevalence compared by visit using
- 8 McNemar's test and by vaccination status using Fisher's exact test. Red dots and lines represent
- 9 median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by
- 10 vaccination status using Wilcoxon rank-sum test. Mean (SD) days since first vaccine: 48 (30).

11

1 References

2

Riffe T AE, Schöley J, Donzowa J, Kniffka M. COVerAGE-DB: A database of COVID-19
 cases and deaths by age. <u>https://data.unicef.org/resources/covid-19-confirmed-cases-and-</u>
 deaths-dashboard/: UNICEF; 2022.

Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive
of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205-11.

8 3. Bartsch YC, Wang C, Zohar T, et al. Humoral signatures of protective and pathological

9 SARS-CoV-2 infection in children. Nat Med 2021;27:454-62.

10 4. Bloise S, Marcellino A, Testa A, et al. Serum IgG levels in children 6 months after SARS-

11 CoV-2 infection and comparison with adults. Eur J Pediatr 2021;180:3335-42.

12 5. Corr M, Christie S, Watson C, et al. Seroprevalence of SARS-CoV-2 antibodies in children

of United Kingdom healthcare workers: a prospective multicentre cohort study protocol. BMJ
Open 2020;10:e041661.

Cotugno N, Ruggiero A, Bonfante F, et al. Virological and immunological features of
 SARS-CoV-2-infected children who develop neutralizing antibodies. Cell Rep 2021;34:108852.

17 7. Cotugno N, Ruggiero A, Pascucci GR, et al. Virological and immunological features of
18 SARS-COV-2 infected children with distinct symptomatology. Pediatr Allergy Immunol
19 2021;32:1833-42.

20 8. Dowell AC, Butler MS, Jinks E, et al. Children develop robust and sustained cross-21 reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol 2022;23:40-9.

1	9.	Garrido C, Hurst JH, Lorang CG, et al. Asymptomatic or mild symptomatic SARS-CoV-2
2	infect	ion elicits durable neutralizing antibody responses in children and adolescents. JCI Insight
3	2021;	6.
4	10.	Liu P, Cai J, Jia R, et al. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing
5	antibo	ody in children with COVID-19. Emerg Microbes Infect 2020;9:1254-8.
6	11.	Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in
7	hospit	alized pediatric and adult patients. Sci Transl Med 2020;12.
8	12.	Renk H, Dulovic A, Seidel A, et al. Robust and durable serological response following
9	pediat	tric SARS-CoV-2 infection. Nat Commun 2022;13:128.
10	13.	Roarty C, Tonry C, McFetridge L, et al. Kinetics and seroprevalence of SARS-CoV-2
11	antibo	odies in children. Lancet Infect Dis 2021;21:e143.
12	14.	Selva KJ, van de Sandt CE, Lemke MM, et al. Systems serology detects functionally
13	distine	ct coronavirus antibody features in children and elderly. Nat Commun 2021;12:2037.
14	15.	Toh ZQ, Higgins RA, Do LAH, et al. Persistence of SARS-CoV-2-Specific lgG in Children 6
15	Mont	hs After Infection, Australia. Emerg Infect Dis 2021;27:2233-5.
16	16.	Waterfield T, Watson C, Moore R, et al. Seroprevalence of SARS-CoV-2 antibodies in
17	childro	en: a prospective multicentre cohort study. Arch Dis Child 2021;106:680-6.
18	17.	Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in
19	childro	en and adults across the COVID-19 clinical spectrum. Nat Immunol 2021;22:25-31.
20	18.	Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and
21	compa	arison of sensitivity to ELISA. Methods 2006;38:317-23.

1	19. Chen P, Datta G, Grace Li Y, et al. First-in-Human Study of Bamlanivimab in a
2	Randomized Trial of Hospitalized Patients With COVID-19. Clin Pharmacol Ther 2021;110:1467-
3	77.
4	20. Benschop RJ TJ, Zhang L, Poorbaugh J, Kallewaard NL, Vaillancourt P, Crisp M, Trinh T,
5	Freitas J, Beasley S, Daniels M, Haustrup N, Higgs R, Nirula A, Cohen M, Marovich M. The effect
6	of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to
7	COVID-19 vaccination. medRxiv 2021.
8	21. Yu Y, Esposito D, Kang Z, et al. mRNA vaccine-induced antibodies more effective than
9	natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Sci Rep 2022;12:2628.
10	22. Chen LL, Chua GT, Lu L, et al. Omicron variant susceptibility to neutralizing antibodies
11	induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. Emerg Microbes
12	Infect 2022;11:543-7.
13	23. Girard B, Tomassini JE, Deng W, et al. mRNA-1273 Vaccine-elicited Neutralization of
14	SARS-CoV-2 Omicron in Adolescents and Children. medRxiv 2022.
15	24. Tang J, Randolph AG, Novak T, et al. Systemic and Lower Respiratory Tract Immunity to
16	SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C. Vaccines (Basel)
17	2022;10.
18	25. Fowlkes AL YS, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech)
19	mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and
20	Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022. In: CDC, ed.
21	MMWR Morb Mortal Wkly Rep2022:422-8.

Page 23

1	26. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection severity in
2	children under 5 years old before and after Omicron emergence in the US. medRxiv 2022.
3	27. Marks KJ WM, Agathis N, Anglin O, Milucky J, Patel K, Pham H, Kirley P, Kawasaki B,
4	Meek J, Anderson E, Weigel A, Kim S, Lynfield R, Ropp S, Spina N, Bennett N, Shiltz E, Sutton M,
5	Talbot K, Price A, Taylor C, Havers F, COVID-NET Surveillance Team. Hospitalization of Infants
6	and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States,
7	March 2020–February 2022. In: CDC, ed. MMWR2022:429-36.
8	28. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up
9	to 8 months after infection. Science 2021;371.
10	29. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861-
11	80.
12	30. Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance
13	and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med
14	2021;2:100204.
15	31. Adamo S, Michler J, Zurbuchen Y, et al. Signature of long-lived memory CD8(+) T cells in
16	acute SARS-CoV-2 infection. Nature 2022;602:148-55.
17	

Table 1. Demographic characteristics according to age and cohort

	Adults, Symptomatic, PCR+ (n=23)		Children (n=67)			
	No Vaccine	Vaccine after visit 1	Symptomatic, PCR+	Symptomatic, no testing or PCR-	Asymptomatic, exposed	Asymptomatic, no known exposure
	N=16	N=7	N=8	N=27	N=13	N=19
Age, years, mean (SD)	37.2 (11.7)	35.9 (8.2)	8.0 (7.1)	7.4 (4.5)	4.5 (4.4)	11.2 (3.4)*
Sex, female, n (%)	10 (62.5)	3 (42.9)	4 (50.0)	8 (29.6)	6 (46.2)	7 (36.8)

*Asymptomatic children with no known exposure were significantly older than asymptomatic, exposed children (p=0.001), Tukey's post-hoc test

Abbreviations: PCR, polymerase chain reaction



Figure 1. Study flowchart



Figure 2. Neutralizing antibody (nAb) prevalence and titers at baseline and 6-month follow-up in (A) children according to study group, (B) all children with nAb at baseline, and (C) comparing children who were in the symptomatic groups to asymptomatic groups. Prevalence compared by visit using McNemar's test and by study cohort using Fisher's exact test, with Bonferroni correction for pairwise comparisons. Red dots and lines represent median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by study cohort using Wilcoxon rank-sum test. #significantly different than all other groups; *p<.05, ** p<.001.



Figure 3. Prevalence and titers of neutralizing antibodies at study baseline and 6-month follow-up in SARS-CoV-2 PCR-positive, symptomatic unvaccinated children and adults. Prevalence compared by visit using McNemar's test and by age group using chi-squared test. Red dots and lines represent median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by age group using Wilcoxon rank-sum test.

Neutralizing Ab

Wild type SARS-CoV-2 antigens



Spike variant antigens



Time point (0- and 6-month follow-up), by age group

Figure 4. Titers at study baseline and 6-month follow-up in SARS-CoV-2 PCR-positive, symptomatic unvaccinated children (n=8) and adults (n=16). Red dots and lines represent median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by age group using Wilcoxon rank-sum test; *p<.05, **p<.01. Antigen definitions included in methods section.



NV, no vaccine after visit 1, n=16 🛛 V, vaccine after visit 1, n=7

Figure 5. Prevalence (A) and titers (B) of neutralizing antibodies (nAb) at baseline and 6-month follow-up in adults who are not vaccinated (NV, n=16) and vaccinated after first visit (V, n=7), and (C) association between titers of nAb at 6-month follow-up and days since first vaccination dose in adults who were vaccinated. Prevalence compared by visit using McNemar's test and by vaccination status using Fisher's exact test. Red dots and lines represent median of titers. Titers compared by visit using Wilcoxon matched-pairs signed-rank test and by vaccination status using Wilcoxon matched-pairs signed-rank test and by vaccination status using Wilcoxon rank-sum test. Mean (SD) days since first vaccine: 48 (30).